MedPath

Calcitriol

Generic Name
Calcitriol
Brand Names
Rocaltrol, Vectical
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
32222-06-3
Unique Ingredient Identifier
FXC9231JVH
Background

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to Vitamin D3 (vitamin D3) in the skin, which is then converted to Calcifediol in the liver and kidneys. Calcifediol undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity . Calcitriol is considered to be the most potent metabolite of vitamin D in humans . Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate . Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system. In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways of classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand . There is also evidence that calcitriol modulates the action of cytokines and may regulate immune and inflammatory response, cell turnover, cell differentiation .

Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing chronic renal dialysis, and osteoporosis. It is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis).

Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Associated Conditions
Hypocalcemia, Mild to Moderate Plaque Psoriasis, Osteodystrophy, Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism

Not Applicable
Completed
Conditions
Hyperparathyroidism
Kidney Disease
Interventions
Drug: Paricalitol
First Posted Date
2008-12-02
Last Posted Date
2012-12-06
Lead Sponsor
Penang Hospital, Malaysia
Target Recruit Count
69
Registration Number
NCT00800358
Locations
🇲🇾

Hospital Sultanah Bahiyah Haemodialysis Unit KM 6 Jalan Langgar, Alor Star, Kedah, Malaysia

🇲🇾

Clinical Research Centre, Penang Hospital, Georgetown, Penang, Malaysia

🇲🇾

Nephrology Department, Tengku Ampuan Rahimah Hospital, Klang, Selangor, Malaysia

and more 8 locations

Phase I/II Calcitriol in Lung Cancer

Phase 1
Terminated
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2008-11-20
Last Posted Date
2017-12-12
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
34
Registration Number
NCT00794547
Locations
🇺🇸

St. Joseph Mercy Hospital, Ann Arbor, Michigan, United States

🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 1 locations

Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis

Phase 2
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2008-10-01
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
88
Registration Number
NCT00763555
Locations
🇨🇦

K. Papp Clinical Research, Inc., Waterloo, Ontario, Canada

🇨🇦

North Bay Dermatology Centre, North Bay, Ontario, Canada

🇺🇸

Minnesota Clinical Study Center, Fridley, Minnesota, United States

and more 3 locations

Vitamin D and Coronary Calcification Study

Phase 4
Completed
Conditions
Vitamin D Deficiency
Disorders of Calcium and Bone Metabolism
Chronic Kidney Disease
Coronary Calcification
Interventions
First Posted Date
2008-09-15
Last Posted Date
2017-12-08
Lead Sponsor
Joslin Diabetes Center
Target Recruit Count
44
Registration Number
NCT00752102
Locations
🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Vitamin D for the Treatment of Severe Asthma

Phase 4
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2008-07-09
Last Posted Date
2009-08-13
Lead Sponsor
Kantonsspital Baselland Bruderholz
Target Recruit Count
20
Registration Number
NCT00712205
Locations
🇨🇭

Department of Medicine, Bruderholz, Baselland, Switzerland

Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer

Not Applicable
Completed
Conditions
Lung Cancer
Precancerous Condition
Tobacco Use Disorder
Interventions
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2008-06-05
Last Posted Date
2018-06-04
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
16
Registration Number
NCT00690924
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Phase 4
Terminated
Conditions
Secondary Hyperparathyroidism
Dialysis
Interventions
First Posted Date
2008-04-23
Last Posted Date
2012-01-20
Lead Sponsor
Abbott
Target Recruit Count
13
Registration Number
NCT00664430
Locations
🇧🇷

Site Reference ID/Investigator# 7118, Sao Paulo, Brazil

🇧🇷

Site Reference ID/Investigator# 7114, Sao Paulo, Brazil

Safety & Effectiveness of Clobex Spray, Followed by Calcitriol Ointment in Management of Plaque Psoriasis

Phase 3
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2008-04-15
Last Posted Date
2022-08-23
Lead Sponsor
Galderma R&D
Target Recruit Count
305
Registration Number
NCT00658788
Locations
🇺🇸

J&J Studies, Inc, College Station, Texas, United States

🇺🇸

Mount Sinai Department of Dermatology, New York, New York, United States

🇺🇸

Virginia Clinical Research, Inc, Norfolk, Virginia, United States

and more 9 locations

Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

Phase 2
Terminated
Conditions
Hypocalcemia
Interventions
First Posted Date
2008-02-26
Last Posted Date
2012-12-06
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
7
Registration Number
NCT00623974
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Bioequivalency Study of Calcitriol Tablets Under Fasting Conditions

Not Applicable
Completed
Conditions
Secondary Hyperparathyroidism
Hypocalcemia
First Posted Date
2008-01-28
Last Posted Date
2018-01-23
Lead Sponsor
Roxane Laboratories
Target Recruit Count
36
Registration Number
NCT00601328
Locations
🇺🇸

Bio-Kinetic Clinical Applications, Inc., Springfield, Missouri, United States

© Copyright 2025. All Rights Reserved by MedPath